Scarica l'app Stockscreener
44.29
0.32%
-0.14
Dopo l'orario di chiusura:
44.70
0.41
+0.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Travere Therapeutics (TVTX) grants director 4,000 shares and 12,000 options - Stock Titan
Travere Therapeutics (TVTX) director receives stock and option awards - Stock Titan
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity - Stock Titan
Travere Therapeutics (TVTX) director granted shares and 12,000 stock options - Stock Titan
Travere Therapeutics (TVTX) director granted shares and 12,000 options - Stock Titan
Travere Therapeutics (TVTX) grants director stock and options - Stock Titan
Travere Therapeutics (TVTX) investors back equity plan boost and all 2026 meeting items - Stock Titan
Travere Therapeutics Rides FILSPARI Surge After FDA Win - TipRanks
Insider Sell Alert: Timothy Coughlin Sells 3,250 Shares of Trave - GuruFocus
Travere Therapeutics (TVTX) director sells 3,250 shares in Rule 10b5-1 trade - Stock Titan
Stephens Investment Management Group LLC Acquires 121,955 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX) - The Globe and Mail
(TVTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
Armistice Capital/Steven Boyd discloses 4,897,417 TVTX shares (5.27%) - Stock Titan
Why Travere Therapeutics Stock Is Tumbling Today - TipRanks
Travere, Ligand Pharma announce FDA label expansion for Filspari - MSN
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Travere Therapeutics launches first FDA-approved therapy for rare kidney disease FSGS. - Pluang
UBS Group AG Has $16.15 Million Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2026 - BioSpace
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
State of New Jersey Common Pension Fund D Takes Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Issues New Convertible Notes to Refinance Debt - TipRanks
Travere Therapeutics Completes $525 Million 0.50% Convertible Notes Offering Led by JPMorgan, Jefferies, Leerink - TradingView
[8-K] Travere Therapeutics, Inc. Reports Material Event - Stock Titan
RTRX6388605 Bond Coupon Analysis — Rate & Payments - TradingView
Travere prices upsized $475.0 million convertible senior notes offering to refinance 2029 convertible notes - MSN
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters - Yahoo Finance
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters - The Motley Fool
MSN Money - MSN
Travere Therapeutics analysts increase their forecasts following Q1 earnings - MSN
RTRX6388605 Bond Price and Chart — FINRA:RTRX6388605 - TradingView
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Travere (TVTX) Q4 2025 Earnings Transcript - AOL.com
Travere Therapeutics Insider Sold Shares Worth $1,092,657, According to a Recent SEC Filing - Moomoo
Travere Therapeutics to Participate at Upcoming Investor ConferencesMay 7, 2026 - BioSpace
Travere Therapeutics Inc SEC Filings - Stock Titan
Travere Therapeutics plans $400M convertible notes offering - MSN
Travere Therapeutics Prices Upsized $475 Million Debt Offering - Moomoo
Travere Therapeutics Insider Sold Shares Worth $988,875, According to a Recent SEC Filing - Moomoo
Travere Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) 2026-05-07 - Seeking Alpha
[424B5] Travere Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case - Sahm
Travere Therapeutics Insider Sold Shares Worth $360,000, According to a Recent SEC Filing - Moomoo
Travere Therapeutics Insider Sold Shares Worth $1,015,086, According to a Recent SEC Filing - marketscreener.com
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes - BioSpace
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):